Back

Ranolazine is associated with a reduced incidence of atrial fibrillation in patients with chronic coronary syndrome: the results of a real-world analysis of an Italian population

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: The role of rate control and comorbidities in atrial fibrillation Rhythm Control, Antiarrhythmic Drugs ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Associate Professor Stefano Fumagalli

Internal and Specialist Medicine and Geriatric Arrhythmia Unit, Florence (Italy)

5 More presentations in this session

Presentation thumbnail
Interactions of circulating, digoxin-like, steroids with rate control therapy for atrial fibrillation in the RATE-AF randomised clinical trial
Doctor I. Akoumianakis (Birmingham, GB)
Abstract Slides Video
Presentation thumbnail
High levels of intermediate cd14++cd16+ monocytes predict incident atrial fibrillation in the general population
Doctor K. Sveen (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
The impact of sick sinus syndrome on flow velocity of the left atrial appendage in patients with atrial fibrillation
Doctor S. Takahashi (Kobe, JP)
Abstract Slides Video
Presentation thumbnail
Clinical impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study
Professor L. Fauchier (Tours, FR)
Abstract Slides Video
Presentation thumbnail
Is pre-diabetes a predictor of events in patients with atrial fibrillation?
Doctor A. Ledo Pineiro (Vigo, ES)
Abstract Slides Video

Access the full session

Session thumbnail
The role of rate control and comorbidities in atrial fibrillation

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources